Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-08-11
1999-10-19
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544345, 540578, 514250, 435 74, 436545, 436815, A61K 31495, A61K 3155, C07D48714
Patent
active
059689285
ABSTRACT:
The invention discloses novel fused-azacylic quinoxalinediones. These compounds may be employed as excitatory amino acid antagonists and as analogs for use in immunological assays. The invention is also directed to both a radioimmunoassay and enzyme immunoassay for detecting and quantitating 1,4,7,8,9,10,-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dion e PNQX and analogs thereof.
REFERENCES:
patent: 4889855 (1989-12-01), Jacobsen et al.
patent: 5081123 (1992-01-01), Honore et al.
patent: 5308845 (1994-05-01), Honore et al.
patent: 5843945 (1998-12-01), Watjen et al.
C.F. Bigge, and T.C. Malone, "Agonists, Antagonists and Modulators of the N-methyl-D-aspartic acid (NMDA) and .alpha.-amino-3-hydroxy-5-isoxazolepropanoic acid (AMPA) Subtypes of Glutamate Receptors", Current Opinion in Therapeutic Patents, 1993, pp. 951-989.
M. Rogawski, "Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines", TiPS, vol. 14, 1993, pp. 325-331.
H. Li and A.M. Buchan, "Treatment with an AMPA Antagonists 12 Hours Following Severe Normothermic Forebrain Ischemia Prevents CA.sub.1 Neuronal Injury", Journal of Cerebral Blood Flow and Metabolism, vol. 13, No. 6, 1993, pp. 933-939.
B. Nellgard and T. Wieloch, "Postischemic Blockade of AMPA but not NMDA Receptors Mitigates Neuronal Damage in the Rat Brain Following Transient Severe Cerebral Ischemia", Journal of Cerebral Blood Flow and Metabolism, vol. 12, No. 1, 1992, pp. 2-11.
R. Bullock et al., "Neuroprotective Effect of the AMPA Receptor Antagonists LY-293558 in Focal Cerebral Ischemia", Journal of Cerebral Blood Flow and Metabolism, vol. 14, No. 3, 1994, pp. 466-471.
D. Xue et al., "Delayed Treatment with AMPA, but Not NMDA, Antagonsists Reduces Neocortical Infarction", Journal of Cerebral Blood Flow and Metabolism, vol. 14, No. 2, 1994, pp. 251-261.
X.-J. Xu et al., "Systemic Excitatory Amino Acid Receptor Antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor and of the N-methyl-D-aspartate (NMDA) Receptor Relieve Mechanical Hypersensitivity After Transient Spinal Cord Ischemia in Rats", The Journal of Pharmacology and Experimental Therapeutics, vol. 267, No. 1, 1993, pp. 140-144.
T. Namba et al., "Antiepileptic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy", Brain Research, vol. 638, 1994, pp. 36-44.
S.E. Browne and J. McCulloch, "AMPA receptor antagonists and local cerebral glucose utilization in the rat", Brain Research, vol. 641, 1994, pp. 10-20.
S. Yamaguchi et al., "Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models", Epilepsy Research, vol. 15, 1993, pp. 179-184.
S. Smith et al., "The non-N-methyl-D-aspartate receptor antagonists, BYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy", European Journal of Pharmacology, vol. 201, 1991, pp. 179-183.
T. Klockgether et al., "The AMPA Receptor Antagonist NMQX Has Antiparkinsonian Effects in Monoamine-depleted Rats and MPTP-treated Monkeys", Annals of Neurology, vol. 30, No. 5, 1991, pp. 717-723.
T. Klockgether et al., "Toward an Understanding of the Role of Glutamate in Experimental Parkinsonism: Agonist-Sensitive Sites in the Basal Ganglia", Annals of Neurology, vol. 34, No. 4, 1993, pp. 585-593.
P. Francis et al., "Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives", Journal of Neurochemistry, vol. 60, No. 5, 1993, pp. 1589-1604.
S. Lipton, "Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide", TINS, vol. 16, No. 12, 1993, pp. 527-532.
S. Lipton and P. Rosenberg, "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders", Review Article in Mechanisms of Disease, F. Epstein, Editor, vol. 380, No. 9, 1993, pp. 613-622.
Bigge Christopher Franklin
Nordblom Gerald David
Yi Chung Stephen
Anderson Elizabeth M.
Kessinger Ann M.
Shah Mukund J.
Warner-Lambert & Company
LandOfFree
Excitatory amino acid antagonists: fused-azacyclic quinoxalinedi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Excitatory amino acid antagonists: fused-azacyclic quinoxalinedi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Excitatory amino acid antagonists: fused-azacyclic quinoxalinedi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2055567